Previous Close | 25.62 |
Open | 25.62 |
Bid | 25.60 |
Ask | 29.90 |
Strike | 105.00 |
Expire Date | 2024-11-15 |
Day's Range | 25.62 - 25.62 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).